Compugen logo

Compugen(CGEN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.84
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CGEN

11/20/2026: CGEN (1-star) is currently NOT-A-BUY. Pass it for now.

Compugen is a clinical-stage biotechnology company that utilizes proprietary computational discovery platforms to identify novel immune checkpoint targets and develop cancer immunotherapies. The company's main strengths lie in its innovative target discovery engine and high-profile partnerships with major pharmaceutical leaders. Its primary growth opportunity centers on advancing clinical-stage candidates like COM701 and expanding into new modalities such as antibody-drug conjugates. Key risks include typical clinical trial uncertainties, high R&D cash burn, and intense competition in the immuno-oncology space. The stock suits growth-oriented investors willing to accept high volatility in exchange for potential clinical breakthroughs, with close attention required on clinical data readouts and partnership updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveCompugen offers exposure to clinical-stage oncology innovation and high potential upside from successful drug development.
Momentum investorStrong fit while signal remains positiveStock price frequently reacts sharply to clinical trial data readouts and partnership announcements.
Value investorWeak fitThe company lacks consistent earnings and commercial product sales, making traditional valuation models inapplicable.
Dividend investorWeak fitCompugen reinvests capital into research and development and does not pay dividends.
Low-risk investorWeak fitClinical-stage biotechnology investing entails high clinical trial and market volatility risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks experience sharp price swings around clinical data releases and regulatory updates.
Valuation riskMedium / highValuations are heavily dependent on future clinical success and pipeline potential rather than current cash flows.
Competition risk (immuno-oncology competition)HighThe company competes with deep-pocketed pharmaceutical giants developing similar checkpoint inhibitors.
Business qualityMediumCompugen features validated discovery platforms and strong partnerships, though commercial maturity is still pending.
Dividend incomeLow / noneNo dividend is paid to investors.
Execution riskHighSuccess relies heavily on navigating complex clinical trials and achieving regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 178.08M USD
Price to earnings Ratio 4.82
1Y Target Price 4.8
Price to earnings Ratio 4.82
1Y Target Price 4.8
Volume (30-day avg) 233.0K shares
Beta 2.82
52 Weeks Range 1.43 - 3.23
Updated Date 11/20/2026
52 Weeks Range 1.43 - 3.23
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.39

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 114.77%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CGEN receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
CGEN has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+348.4%) and strong cash generation (FCF margin 43.1%) are partially offset by very low insider ownership of 0.39%.

Financial Health Rating

★★★★★
CGEN's financial health is supported by strong profitability, including gross margin of 87.3% and operating margin of 43.1%. Cash strength is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CGEN's strongest growth driver at +348.4% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+161.1%, strong) is also strong, while free-cash-flow growth (-36.7%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 15.0% (soft) and 99.8% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.39%, which materially reduces the ownership score.

Unit Economics (Per $1K Revenue)

★★★★★
CGEN generates approximately $873 of gross profit, $431 of operating income, and $431 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.15%

Quantitative Style Profile

★★★★★
CGEN has a high-quality, liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedQuality TiltHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Research Collaborations and LicensingUpfront licensing fees, research funding, and milestone payments from pharmaceutical partners.Revenue is event-driven and arrives when partners advance pipeline drugs or achieve development milestones.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 4.82
Forward PE 12.36
Enterprise Value 75.81M
Price to Sales(TTM) 2.35
Enterprise Value 75.81M
Price to Sales(TTM) 2.35
Enterprise Value to Revenue 1
Enterprise Value to EBITDA 2.42
Shares Outstanding 94.72M
Shares Floating 94.56M
Shares Outstanding 94.72M
Shares Floating 94.56M
Percent Insiders 0.39
Percent Institutions 15

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.